Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
Hana Niebur, MD, assistant professor at the University of Nebraska Children’s Hospital and Medical Center, discusses non-infectious complications of primary immune deficiency. Lung disease is the most common…
Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma, reviews treatment options for acute myeloid leukemia (AML) patients. Dr. Krivoshik states that, while patients traditionally receive…
Arkadiusz Z. Dudek, MD, medical oncologist at Regions Hospital Care Center in St. Paul, Minnesota, discusses a phase 2 trial of nivolumab plus ramucirumab in previously treated mesothelioma…
Researchers from UC Davis Comprehensive Cancer Center discuss results from their recent study on long term complications adolescents and young adults face after treatment for acute myeloid leukemia…
Jorge Cortes, MD, director of the Georgia Cancer Center in Augusta, GA, provides a comprehensive look at the current challenges specialists face in providing optimal treatment for patients…
Donald B. Kohn, MD, of the University of California, Los Angeles, discusses hematopoietic stem cell gene therapy for primary immune deficiencies. Up to 89% of patients receiving hematopoietic…
Rahul Seth, DO, assistant professor of medicine at Upstate University Hospital, provides recommendations for the treatment of melanoma. For patients with unresectable melanoma, Dr. Seth recommends a combination…
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses side effects associated with the novel…
A recent study published in Cell Communication and Signaling presents evidence that cancer treatments that utilize adenoviruses for targeted treatment delivery may trigger additional glioma stem cell formation…
Alessia Cavazza, PhD, of Great Ormond Street Institute of Child Health (ICH) at University College London, discusses her research related to the potential of emerging gene-editing technologies, particularly…
